Conference Coverage

COVID smell loss tops disease severity as a predictor of long-term cognitive impairment


 

FROM AAIC 2022

Longest follow-up to date

Commenting on the research, Heather Snyder, PhD, vice president, medical and scientific relations at the Alzheimer’s Association, noted the study is “the longest follow-up we’ve seen” looking at the connection between persistent loss of smell and cognitive changes after a COVID-19 infection.

The study included a “fairly large” sample size and was “unique” in that it was set up in a part of the country with centralized testing, said Dr. Snyder.

The Argentinian group is among the most advanced of those connected to the CNS SC2, said Dr. Snyder.

Members of this Alzheimer’s Association consortium, said Dr. Snyder, regularly share updates of ongoing studies, which are at different stages and looking at various neuropsychiatric impacts of COVID-19. It is important to bring these groups together to determine what those impacts are “because no one group will be able to do this on their own,” she said. “We saw pretty early on that some individuals had changes in the brain, or changes in cognition, and loss of sense of smell or taste, which indicates there’s a connection to the brain.”

However, she added, “there’s still a lot we don’t know” about this connection.

The study was funded by Alzheimer’s Association and FULTRA.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

More evidence the flu vaccine may guard against Alzheimer’s
MDedge Psychiatry
Can bone density scans help predict dementia risk?
MDedge Psychiatry
Scientists find brain mechanism behind age-related memory loss
MDedge Psychiatry
PTSD may accelerate cognitive decline over time
MDedge Psychiatry
Understanding the neuroscience of narcissism
MDedge Psychiatry
Hospital programs tackle mental health effects of long COVID
MDedge Psychiatry
Metabolic syndrome raises dementia risk in under-60s
MDedge Psychiatry
ICU stays linked to a doubling of dementia risk
MDedge Psychiatry
Novel guidance informs plasma biomarker use for Alzheimer’s disease
MDedge Psychiatry
Smell loss may be a biomarker of Alzheimer’s disease risk
MDedge Psychiatry